Double filtration plasmapheresis maintains normal adhesion molecule levels.
Levels of plasma soluble vascular cell adhesion molecule-1 (sVCAM-1), soluble intercellular adhesion molecule-1 (sICAM-1), and von Willebrand factor (vWF) increase in patients with peripheral vascular or ischemic heart disease. These factors are related to the progression of atherosclerosis. Furthermore, these substances and thrombomodulin (TM) are indicators for assessing the degree of damage to the endothelium. To evaluate the effect of double filtration plasmapheresis (DFPP) on these molecules, the plasma levels of vWF, sICAM-1, sVCAM-1, and TM were measured in 4 familial hypercholesterolemia (FH) patients who underwent treatment with DFPP at 2 week intervals for more than 3 years. The levels of sVCAM-1 and sICAM-1 in hypercholesterolemia patients with ischemic heart disease as a control was 773 +/- 109 and 334 +/- 82 ng/ml. These values were higher than the normal value. In the FH patients who underwent DFPP treatment, the average sICAM-1 levels were 221 +/- 47 and 197 +/- 36 ng/ml before and after, respectively. The average sVCAM-1 levels were 601 +/- 87 and 486 +/- 60 ng/ml. There were no significant differences between the pre- and post-DFPP values. The activities of plasma vWF before and after DFPP treatment were 158 +/- 23 and 45 +/- 9%. The levels of plasma TM before and after treatment were 3.0 +/- 0.3 and 3.4 +/- 0.5 FU/ml. From these results, it is suggested that DFPP treatment does not damage the endothelium and may prevent the progression of atherosclerosis by removing the substances that induce the production of sICAM-1 and sVCAM-1 due to long-term treatment.
Yamane
S
S
Tokatsu Clinic Hospital, Matsudo, Chiba, Japan.
Matsugane
T
T
Motohashi
K
K
Nobuto
T
T
Azuma
N
N
Nishide
T
T
Suzuki
M
M
D000924:Anticholesteremic Agents / Q000627:therapeutic use; D001161:Arteriosclerosis / Q000097:blood / Q000473:pathology / Q000517:prevention & control; D015415:Biomarkers / Q000097:blood; D015815:Cell Adhesion Molecules / Q000097:blood*; D002784:Cholesterol / Q000097:blood; D018450:Disease Progression; D004730:Endothelium, Vascular / Q000473:pathology; D005374:Filtration / Q000379:methods; D005500:Follow-Up Studies; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D006937:Hypercholesterolemia / Q000097:blood / Q000628:therapy; D006938:Hyperlipoproteinemia Type II / Q000097:blood / Q000628:therapy; D018799:Intercellular Adhesion Molecule-1 / Q000097:blood; D017202:Myocardial Ischemia / Q000097:blood / Q000473:pathology / Q000628:therapy; D016491:Peripheral Vascular Diseases / Q000097:blood / Q000473:pathology; D010956:Plasmapheresis / Q000379:methods*; D017035:Pravastatin / Q000627:therapeutic use; D018180:Thrombomodulin / Q000097:blood; D019010:Vascular Cell Adhesion Molecule-1 / Q000097:blood; D014841:von Willebrand Factor / Q000032:analysis
D000924:Anticholesteremic Agents; D015415:Biomarkers; D015815:Cell Adhesion Molecules; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D018180:Thrombomodulin; D019010:Vascular Cell Adhesion Molecule-1; D014841:von Willebrand Factor; D018799:Intercellular Adhesion Molecule-1; D002784:Cholesterol; D017035:Pravastatin